Schäferhoff, Marco

Global health 2050: the path to halving premature death by mid-century

Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., et al. (2024) · The Lancet

Global Health Care IssuesGlobal Health and Epidemiology

Cited by 125

Alma Ata at 40 years: reflections from the Lancet Commission on Investing in Health

Watkins, D. A., Yamey, G., Schäferhoff, M., Adeyi, O., Alleyne, G., Alwan, A., Berkley, S., Feachem, R., Frenk, J., Ghosh, G., et al. (2018) · The Lancet

Global Health Care IssuesHealthcare Systems and Reforms

Cited by 105

Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis

Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., et al. (2023) · The Lancet

Tuberculosis Research and EpidemiologyInfectious Diseases and Tuberculosis

Cited by 87

How much donor financing for health is channelled to global versus country-specific aid functions?

Schäferhoff, M., Fewer, S., Kraus, J., Richter, E., Summers, L. H., Sundewall, J., Yamey, G., & Jamison, D. T. (2015) · The Lancet

International Development and AidPublic health and occupational medicine

Cited by 54

International funding for global common goods for health: an analysis using the Creditor Reporting System and G-FINDER databases

Schäferhoff, M., Chodavadia, P., Martinez, S., McDade, K. K., Fewer, S., Silva, S., Jamison, D., & Yamey, G. (2019) · Health Systems & Reform

International Development and AidPublic health and occupational medicine

Cited by 32

Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries

Schäferhoff, M., Zimmerman, A., Diab, M. M., Mao, W., Chowdhary, V., Gill, D., Karanja, R., Madikizela, M., Ogbuoji, O., & Yamey, G. (2022) · The Lancet Global Health

Pharmaceutical Economics and PolicyHealth Systems, Economic Evaluations, Quality of Life

Cited by 11